氧气驱动联合雾化吸入特布他林与布地奈德治疗慢性支气管炎临床疗效观察

Clinical Effect of Oxygen Driving Combined with Aerosol Inhalation of Terbutaline and Budesonide on Patients with Chronic Bronchitis

目的探讨氧气驱动联合雾化吸入特布他林雾化液与布地奈德雾化混悬液治疗慢性支气管炎的临床疗效。方法选取2011年1月—2013年2月我院呼吸内科收治的慢性支气管炎患者240例,按照入院先后顺序将其分为观察组和对照组,各120例。对照组给予常规抗感染、静脉滴注平喘药和祛痰药等治疗,观察组在对照组治疗基础上采用氧气驱动联合雾化吸入特布他林雾化液与布地奈德雾化混悬液治疗。比较两组疗效及不良反应发生率。结果观察组治疗总有效率为95.00%(114/120),高于对照组的76.67%(92/120)(P<0.05)。观察组不良反应发生率为3.33%(4/120),低于对照组的7.50%(9/120)(P<0.05)。结论采用氧气驱动联合雾化吸入特布他林雾化液与布地奈德雾化混悬液治疗慢性支气管炎临床效果显著,有效地提高了用药安全性和患者生活质量,值得推广。

Objective To explore the clinical effect of oxygen driving combined with aerosol inhalation of terhutaline and budesonide on patients with chronic bronchitis. Methods 240 patients with chronic bronchitis admitted to our hospital from January 2011 to February 2013 were divided into groups observation and control according to the order of admission, each of 120 cases. Control group was given conventional treatment, such as anti - infective, anti - asthmatic drugs and expectorant drugs, observation group was given oxygen driving combined with aerosol inhalation of terbutaline and budesonide on basis of control group. The effect and incidence of adverse reactions were compared between two groups. Results The total efficacy of observa- tion group was 95.00% （ 114/120）, higher than that of control group of 7.50% （9/120） （P 〈0. 05）. The incidence of ad- verse reactions of observation group was 3.33% （4/120） , lower than that of control group of 7. 50% （9/120） （P 〈0.05）. Conclusion Oxygen driving combined with aerosol inhalation of terbutaline and budesonide in treating patients with chronic bronchitis can improve drug safety and quality of life, being obviously effective.